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SELECTIVE PARP-l TARGETING FOR
DESIGNING CHEMO/RADIO SENSITIZING
AGENTS

Thus, While PARP-l remains a promising therapeutic
target, the discovery of multiple PARPs raises questions of
inhibitor selectivity not heretofore considered.

CLAIM OF PRIORITY

SUMMARY OF THE INVENTION

The invention provides the identi?cation of a Src-homol

This application claims priority from US. provisional
patent application Ser. No. 60/296,110, ?led Jun. 7, 2001.
FIELD OF THE INVENTION

ogy 3 (SH3) domain (domain C; SEQ ID NO: 1) and an SH3
ligand domain (PXXP motif) (SEQ ID NO: 2) on the
10

poly(ADP-ribose) polymerase-1 (PARP-l) protein (SEQ ID
NOS: 4 and 6). The invention also provides that these

The invention relates generally to cancer treatment, and in

domains are involved in PARP-l activation. The mechanism

particular to overcoming cellular resistance to antitumor

of PARP-l activation resembles that of src-tyrosine kinase
activation. Accordingly, the invention provides neW meth
ods for selectively targeting the SH3 domain of PARP-l.

agents.
5

BACKGROUND OF THE INVENTION

The overall importance of this invention is a neW under

DNA repair is a mechanism of resistance to antitumor

DNA damaging agents and to radiotherapy. Rosen EM et al.,
Cancer Invest. 17(1): 56472 (1999). The ability of cancer

20

cells to recogniZe and repair DNA damage in?icted by

standing of the structural mechanisms of enZymes involved
in poly ADP-ribosylation and the utiliZation of this neW
information in the design of selective inhibitors of the
PARP-l enZyme. Thus, the invention involves a paradigm
shift in the design of inhibitors for this anticancer target.

cancer therapy is an important mechanism of resistance to

In one embodiment, the invention provides a method for

treatment. Thus, inhibition of DNA repair is a key strategy
in enabling cancer therapy.

identifying agents that activate PARP-l, including the steps

Activation of the poly(ADP-ribose) polymerase-1

of:
(a) contacting a test compound With PARP-l or a func

25

(PARP-l) enZyme is an immediate cellular response to

tional fragment thereof, Wherein the functional frag

genotoxic stress and is part of a genomic surveillance

ment contains the PARP-l SH-3 domain, the PARP-l

mechanism that responds to DNA damage, triggering sig

SH3-ligand domain, or both domains;

(b) assaying Whether contacting the compound results in

naling events that can lead to cellular recovery. PARP-l is

speci?cally activated by binding to DNA strand breaks.

30

PARP-l has been shoWn to be a target for the development
of radio and chemo sensitizing agents in cancer treatment as
Well as providing protection from stroke. SZabo C & DaW
son V L, Trends Pharmacol Sci. 19(7): 287498 (1998).
Current inhibitors target a conserved catalytic domain of

35

activation of PARP-l; and
(c) identifying the test compound as a compound that
activates PARP-l.
In another embodiment, the invention provides a method

for identifying agents that inactivate PARP-l, including the
steps of:

poly(ADP-Ribose) polymerase-1 (PARP-l) present in all of

(a) contacting a test compound With PARP-l or a func

the PARP family members. Ruf A. et al., Biochemistry
37(11): 38934900 (1998); Tentor‘i L et al., Pharmacol Res.
45(2): 73485 (2002); Jacobson M K & Jacobson E L, Trends
Biochem Sci. 24(11): 41547 (1999).
Knockout experiments have shoWn that the therapeutic

tional fragment thereof, Wherein the functional frag
ment contains the PARP-l SH-3 domain, the PARP-l

SH3-ligand domain, or both domains;

(b) assaying Whether contacting the compound results in

40

inactivation or prevents activation of PARP-l; and
(c) identifying the test compound as a compound that

bene?ts of PARP-l inhibition are a direct result of the

selective inhibition of PARP-l. Shall S & de Murcia G,
Mural. Res. 4601: 1415 (2000). Although PARP-l knockout
is not lethal, it leads to genomic instability and enhances the
cytotoxicity of DNA damaging agents used in cancer
therapy. Several PARP-l inhibitors are currently in preclini
cal development for cancer therapy. Each of these inhibitors
targets the binding site of the required substrate of the
enZyme, nicotinamide adenine dinucleotide (NAD). WhiteA
W et al., J. Med. Chem. 43: 4084497 (2000).
Until recently, PARP-l Was the only knoWn enZyme With
ADP-ribose polymerizing activity. PARP-l has noW been
found to be one of a family of enZymes With PARP activity.
Jacobson M K & Jacobson E L, Trends Biochem. Sci. 24:

inactivates or prevents activation of PARP-l.

In yet another embodiment, the invention provides a
45

of

50

a) providing the structure of the PARP-l SH-3 domain or
the PARP-l SH3 -ligand domain in a digital format that
can be used by a molecular modeling computer pro
gram;

55

(b) obtaining the structure of a compound suspected of
molecularly interacting With the PARP-l SH-3domain
or the PARP-l SH3-ligand domain;
(c) providing the structure of the compound suspected of
molecularly interacting With the PARP-l SH-3 domain
or the PARP-l SH3-ligand domain in a digital format

41547 (1999). Amino acid sequence comparisons of the
members of the PARP family indicate that there is similarity
in their NAD binding sites (pADPRT domain, see, FIG. 1A).
Thus, the current inhibitors lack selectivity, because they
target an NAD binding site common to all PARP family
members.
A double knockout of PARP-l and PARP-2 results in an

embryonic lethal. Schreiber V. et al., J. Biol. Chem. (2002).
PARP-l inhibitors have also inhibit PARP-2, thus it is likely
that the current strategy of inhibitor design may lead to toxic
effects. Perkins E. et al., Cancer Res. 61(10): 4175483

(2001).

method for designing PARP-l inhibitors, including the steps

that can be used by the molecular modeling computer
Program;

(d) operating the molecular modeling computer program
60

to determine

(i) Whether the PARP-l SH-3 domain molecularly
interacts With the compound suspected of molecu
larly interacting With the PARP-l SH-3 domain, or
(ii) Whether the PARP-l SH3-ligand domain molecu
65

larly interacts With the compound suspected of
molecularly interacting With the PARP-l SH3-ligand
domain; and

US 7,072,771 B2
4

3
(e) identifying a compound that interacts molecularly as a

(P_humsh3; SEQ ID NO: 30), bovine (P_bovsh3; SEQ ID
NO: 31), chicken (P_chksh3; SEQ ID NO: 32) and Xenopus
(P_xensh3; SEQ ID NO: 33).

potential therapeutic agent.
In a speci?c embodiment, small peptides With the
sequence RIAPEAPV (SEQ ID NO: 7) compete With the
natural ligand of PARP-1 protein to affect PARP-1 activity.

DETAILED DESCRIPTION OF THE
INVENTION

BRIEF DESCRIPTION OF THE DRAWINGS

PARP-1 and the unique post-translational modi?cation it
catalyZes have previously been considered to function only

FIG. 1 is a set of graphic representations of enZymes in the

PARP family. FIG. 1A shoWs the overall domain organiZa
tion of PARP family members, PARP-1 (SEQ ID NOS: 4
and 6); PARP-2 (SEQ ID NOS: 9 and 11); PARP-3 (SEQ ID

in the cellular surveillance of genotoxic stress. HoWever, the
recent identi?cation of multiple members of a PARP family
might force a revision and expansion of this concept.
PARP-1 is a unique 114 kDa multidomain biosensor that
recogniZes DNA strand breaks introduced in the genome of

NO: 13); tankyrase (SEQ ID NO: 15) and vault-PARP (SEQ
ID NO: 17). All PARPs contain a conserved poly ADP
ribosylation domain. Some also contain a DNA binding

eukaryotic cells exposed to radiation or genotoxic agents.
The recognition of DNA nicks by tWo Zinc ?ngers domains
of PARP-1 (domain A, FIG. 1), found at its N-ter'minus,

domain (A, A', A") and protein interaction domains (D, G).
The conserved ADPRT-fold also found in bacterial toxins

(domain F) is shoWn in the ribbon diagram of the structure
of CF-PARP-l. As provided in this invention, PARP-1
contains a SH3 domain (C) and SH3 ligand. FIG. 1B shoWs

20

the activation mechanism of PARP-1 described in this
application, involving the formation of a PARP-1
homodimer through the intermolecular interaction of an SH3

and SH3 ligand domains.
FIG. 2 is a pictorial description of the ADP-ribose poly
mer cycle. Polymer biosynthesis involves the action of
PARP-1, Which utiliZes NAD. ADP-ribose polymers are

dinucleotide (NAD) as a substrate. PARP-1 synthesiZes

ADP-ribose polymers from NAD+ by attaching NAD+ to
glutamic acid of acceptor proteins such as histones, P53 and
25

DNA pol[3 and XRCC1. The NAD is covalently linked to the
30

terminal ADP-ribose moiety of the elongating ADP-ribose
polymer. RufA et al., Proc. Natl. Acad. Sci. USA 93(15):
74815 (1996).
The active site of all PARPs contain a conserved glutamic
acid residue Which enables a nucleophilic attack on the

domain or ADPRT on the right. The all alpha domain forms

a pocket for the binding of the adenine portion the NAD
substrate (also knoWn as the donor site). The ADPRT fold
binds the acceptor site or elongating poly(ADP-ribose)
polymer. The PXXP SH3 ligand (SEQ ID NO: 2) lies in a
loop at the interface betWeen the all alpha domain and the
ADPRT fold. The gain of function mutation L613F (SEQ ID
NO: 18) maps to the all alpha helical domain right at the

proteins involved in the formation of DNA repair com

plexes, such as the Base Excision repair complex (BASC),

short lived and degraded by poly(ADP-ribose) glycohydro
lase (PARG).
FIG. 3 is a ribbon draWing of the catalytic fragment of
PARP-1 (CF-PARP-l). The N-terminal all alpha domain is
on the left side of the ?gure and the ADP-ribosyltransferase

triggers the activity of the catalytic of CF-PARP-l (domain
E+F, FIG. 1) by 500-fold. PARP-1 attaches ADP-ribose
(ADPR) to itself (domain D, FIG. 1A) and a groWing array
of nuclear protein acceptors using nicotinamide adenine

glycosidic bond to the nicotinamide portion of NAD by the
2' hydroxyl of the terminal ADPR unit of the terminal
35

polymer. The adenine portion of NAD binds in a deep pocket
of the CF-PARP-l structure, While the nicotinamide portion
of NAD binds in a shalloW cavity.
The use of NAD+ as a substrate by PARP-1 establishes a

40

interface Where the PXXP motif is localiZed.
FIG. 4 shoWs the structure of CF-PARP-l and its inhibitor

link betWeen poly ADP-ribosylation and the energy status of
the cell. In situations of massive DNA damage, PARP-1 is

hyperactivated. NAD+ depletion folloWs, resulting in cellu

the terminal ADP-ribose unit of the polymer (acceptor site).

lar necrosis. Thus, regulation of PARP-1 activity is at a
crucial intersection in the cellular fate.
The observation that there is essentially no detectable
poly(ADP-ribose) in resting cells suggests that PARPs are

FIG. 5 is a diagram of the tertiary structure of a typical

generally inactive and, therefore, tightly regulated in vivo.

complexes. The NAD substrate binding site (donor site) With
the adenine moiety binding is in a deep pocket, While the
nicotinamide portion is localiZed in a shalloW pocket next to

45

Smith S, Trends Biochem. Sci. 26: 174*179 (2001).

SH3 module, shoWing the surface responsible for recogni
tion of the PXXP ligand. TWo clusters of aromatic residues
in the sequence form the peptide-binding surface. The
conserved YDF motif (SEQ ID NO: 19) is found at the
N-terminal end of the SH3 sequence at the beginning of the
?rst loop (also knoWn as RT-loop). The WXXPXXY motif
(SEQ ID NO: 20) is found at the C-terminal end just before
the very last strand. The tWo loops surrounding the peptide
binding surface contribute to the speci?city of the interac
tion.

Cancer cells are able to evade programmed cell death
50

tion through cleavage by Caspase-3. Smulson M E et al.,
Adv. Enzyme Regul. 40: 183*215 (2000). Consequently,

55

cancer cells retain the ability to signal DNA repair in
response to single strand breaks. PARP-1 inhibition in
cancer cells mimics its apoptotic inactivation and disables
recovery of cancer cells exposed to radiologic or chemo

therapeutic agents.

FIG. 6 is a sequence alignment of a select group of SH3

domains (top 7 sequences) Whose structures have been
determined and deposited in the PDB database (?rst three

(apoptosis) by a mechanism that involves PARP-1 inactiva

60

Current inhibitors of PARP-1 have targeted the catalytic
fragment of PARP-1, Which contains an NAD binding site.
Bousquet J A et al., Biochemistry 39: 7722*35 (2000). The

letters of the sequence identi?cation indicates the PDB

current inhibitors of PARP-1 are derivatives of benZamides

code): 1AEY (SEQ ID NO: 21); 1AOJ_A (SEQ ID NO: 22);
1AZE_A (SEQ ID NO: 23); 1AON_B (SEQ ID NO: 24);
1ABO_A (SEQ ID NO: 25); 1ARK (SEQ ID NO: 26);

and fused ring heterocycles that bind to the nicotinamide
cavity and inhibit PARP-1 by competing With NAD sub
strate. US. Pat. Nos. 6,201,020, 6,121,278, 5,587,384,

P53BP (SEQ ID NO: 29). The bottom 6 sequences are those
from the C domain of PARP-1 from mouse (P_mussh3; SEQ

ID NO: 28), rat (P_ratsh3; SEQ ID NO: 29), human

65

5,215,738; 5,041,653 and 5,032,617. HoWever, because all
PARPs contain this conserved binding, the current PARP-1

inhibitors lack selectivity.
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This invention addresses this selectivity issue by provid

PARP-l is a Member of a NeW Family of Poly ADP

ing an understanding of the mechanism of PARP-l activa
tion, at the molecular level. As described below, the inven

out mice revealed that polymer metabolism Was not dis

tion puts forWard the involvement of an SH3 domain

rupted in PARP-l knockout mice. Shieh W M et al., J. Biol.

(domain C, FIG. 1; SEQ ID NO: 1) and an SH3-ligand
domain (PXXP motif; SEQ ID NO: 2).
This invention provides a paradigm shift in the design of

gested functional redundancy in the production of poly
(ADP-ribose). TWo closely related PARPs (PARP-2 (SEQ

Ribosylating Proteins. The development of PARP-l knock
Chem. 273(46): 30069472 (1998). This information sug
ID NOS: 9 and 11) and PARP-3 (SEQ ID NO: 13)) Were
identi?ed in human and Drosophila. Johansson M, Genom
ics 57(3): 4425 (1999); Ame J C et al, J. Biol. Chem.
274(25): 1786048 (1999); KaWamura T et al., Biochem.
Biophys. Res. Commun. 251(1): p. 35410 (1998).

PARP-l inhibitors, Where the molecular target is a protein
interaction interface involved in triggering PARP-l activity
once PARP-l recogniZes damaged DNA, rather than the
NAD+ binding site, Where all current inhibitor effort has
been focused. As described beloW, PARP-l activation result
ing from DNA strand break recognition results from the

The ?rst neW PARP member identi?ed Was tankyrase

(Smith S et al., Science 282(5393): 148447 (1998)), also a

action of an SH3 protein interaction module on PARP-l that

multidomain protein containing the protein interaction mod
ules ankyrin repeats and SAM domains (SEQ ID NO: 15).
Tankyrase is responsible for the ADP-ribosylation of TRF1,
a protein involved in the assembly and disassembly of the

potentiates the catalytic dimer. Accordingly, the present
invention provides for the development of a neW drug

discovery paradigm for generation of PARP-l inhibitors for
cancer therapy, by affecting function by allosteric mecha
nisms. DeDecker B S, Chem. Biol. 7(5): Rl03i7 (2000).
Poly(ADP-ribose) polymerase-1 (PARP-l) is a Key Bio
synthetic Target for Drug Discovery. The PARP-l enZyme

20

telomerase in cancer cells.

has been puri?ed and the gene has been characterized.
Cherney B W et al., Proc. Natl. Acad. Sci. USA 84(23):
837044 (1987); Kurosaki T et al., J. Biol. Chem. 262(33):
1599047 (1987); Uchida K et al., Biochem. Biophys. Res.
Commun. 148(2): 617422 (1987); Auer B et al., DNA 8(8):
575480 (1989). The availability of this information led to

25

further developments: (1) structural and site directed
mutagenesis studies enabling the de?nition of several func
tional domains including tWo Zinc ?nger domains at the
N-terminal (FIG. 1A) that bind to DNA strand breaks, an

30

internal automodi?cation domain similar to that found in the
C-terminus of the breast cancer gene (BRCT domain), and
a C-terminal catalytic fragment containing a conserved

The second neW member of the PARP family identi?ed
Was vault PARP (SEQ ID NO: 17). Kickhoefer VA et al., J.
Cell Biol. 146(5): 917428 (1999). Vault PARP is also a

multidomain protein containing the BCRT protein interac
tion domain, present in PARP-l and several DNA repair
proteins. Vault PARP is a large protein-RNA complex found
in the cytoplasm, and currently thought to mediate the
transport of mRNA.
The single conserved domain found in all PARPs is a

catalytic fragment of PARP-l (CF-PARP-l). The structure
of CF-PARP-l Was recently determined by Ruf et al., Proc.
Natl. Acad. Sci. USA 93(15): 74815 (1996), and revealed a
35

NAD"; (2) the generation of PARP-l “knockout” mice that,
despite having a normal development and the capability of

conserved ADP-ribosyltransferase domain (ADPRT, domain
F) core structure also found in bacterial toxins. Like
ADPRTs, PARP contains an NAD+ recognition site. A
detailed comparison of the structure of PARP With the toxins

generating ADPR polymers, are very sensitive to genotoxic
stress and have a shorter life span; (3) the detection of the
cleavage of PARP-l by caspases at the DED sequence motif
found at the very end of the Zinc ?nger domain (Nicholson,

40

D W et al., Nature 376(6535): 37443 (1995)); (4) the
structural determination of the catalytic domain of PARP-l
(CF-PARP-l) (Ruf, A et al., Proc. Natl. Acad. Sci. USA
93(15): 748145 (1996)), Which has structural homology to
the ADP-ribosyl transfer (ADPRT) domain of diphtheria,
cholera, pertussis and enterotoxins; and (5) the identi?cation
of PARP-l inhibitors, targeting the shalloW nicotinamide

45

shoWed a conserved catalytic glutamic acid at the beginning
of the ?fth stand ([35) of the ADPRT fold (see, FIG. 4).
PARP Activation Requires Self-association. The relation
ship betWeen the oligomeric state of PARP-l and its acti
vation has been investigated by several techniques, includ

ing

sedimentation

equilibrium,

gel

permeation,

electrophoretic mobility and kinetics measurements. Juarez
Salinas H et al., Anal. Biochem. 131(2): 41048 (1983).
PARP-l in its activated form is a homodimer, but the

pocket, and used in cancer therapy as radio and chemosen

sitiZing agents. White A W et al., J. Med. Chem. 43(22):
4084497 (2000); Schlicker A et al., Int. J. Radial. Biol.

T-loop structure found at the ends of the chromosomes.
Tankyrase serves to regulate the function of TRF1 and thus,
is a potentially neW target for inhibiting the action of

50

75(1): 914100 (1999)).

structural elements required for dimeriZation remain
unknoWn. The presence of the protein interaction domain,
BRCT, suggests that BRCT may potentiate dimeriZation.
BRCT domains are found in several DNA repair proteins
leading to the formation of the BRCA-associated genome

Thus, PARP-l functions as a cellular biosensor of DNA

surveillance complex or BASC and the DNA-base excision

strands breaks, triggering the poly ADP-ribosylation of
chromatin and DNA repair proteins. The recognition of

complex (BEC). PARP-l may have a regulatory/assembly
function in the formation of these complexes through ADP

55

strand breaks results in at least a 200-fold increase in

ribosylation.

enZyme activity. The catalytic domain serves tWo functions:
(1) automodi?cation of PARP at conserved glutamate resi
dues localiZed in the BRCT domain, through the formation
of dimers. MendoZa-AlvareZ H & AlvareZ-GonZaleZ R, J.

Biol. Chem. 268(30): 22575480 (1993); and (2) the ADP

The structure of Drosophila PARP-l suggested that
PARP-l protein interactions occurred through a conserved
leucine Zipper at the N-terminus of the BRCT domain.
Uchida K et al., Proc. Natl. Acad. Sci. USA 90(8): p. 348145
(1993). Evidence in support of this model include: (1) the

ribosylation of other protein acceptors including histones
and DNA-repair complexes. The ADP-ribosylation of his

C-terminal apoptotic cleavage product (lacking only the Zinc
?nger domains) inhibits dimeriZation and consequently

tones by PARP is thought to be an important step in
chromatin decondensation, Which may be part of an overall
mechanism of freeing the damaged DNA While at the same

time recruiting the action of DNA repair complexes.

60

65

PARP-l activation (Kim, J W et al., J. Biol. Chem. 275(11):
81215 (2000)); and (2) deletion mutant analyses of PARP-l
have been used to map the dimeriZation domain to the

vicinity of the BRCT domain containing the putative leucine
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Zipper motif. The recent structural determination of the
BRCT domain of XRCC1 (Marintchev A et al., Nat. Slrucl.

contain the PXXP SH3 binding core motif, While PARP-3,
tankyrase and vault-PARP shoW little sequence conservation
in this loop, Which is not only surface accessible, but also
lies behind the active site of PARP-1, such that its extension
residues form part of the PARP-1 active site.

Biol. 6(9): 884e93 (1999)) and sequence alignment of the
BRCT family, including PARP-1-BRCT (Bork P et al.,
FASEB J. 11(1): 68e76 (1997)), maps the putative leucine
Zipper motif to a surface-exposed N-terminal helix (otl) of
this ot/[3 structure. In the crystal structure of XRCC1, the

TABLE I

BRCT domain helix al was found to be involved in
Peptide Sequence

homodimeriZation and Was proposed to mediate protein
interactions in vivo.
SH3 Protein Interaction Modules and Enzyme Activation.

PARP Protein Alignment
PARP-l
PARP-l
PARP-l
PARP-2
PARP-2

Many proteins, including the src family of tyrosine kinases,
are regulated by the interaction of SH3 and SH3-ligand
domains. Dalgamo D C et al. Biopolymers 43: 383e400

(1997).
Cells use protein interaction modules (SH2, SH3, EH,
PDZ, WW, PTB) in the recruitment of active molecules into
multiprotein signal complexes or in the activation of dor
mant enZymes. One of these interaction modules is the SH3

domain that binds to proline-rich peptide sequences With the
consensus sequence, PXXP (SEQ ID NO: 2), Which forms
a left-handed polyproline type II helix (PPII). Kuriyan J &
CoWbum D, Annu. Rev. Biophys. Biomol. Slrucl. 26: 259*88

20

human
mouse
rat
human
mouse

GLRIAPPEAPVT—————GYMF:
GLRIAPPEAPVT—————GYMF:
GLRIAPPEAPVT—————GYMF:
GLRIAHPEAPIT—————GYMF:
GLRVAPPEAPIT—————GYMF:

SEQ
SEQ
SEQ
SEQ
SEQ

ID
ID
ID
ID
ID

NO
NO
NO
NO
NO

41
42
43
44
45

PARP-3 human
tankyrase

GLRIMPHS ——————— ——GGRV:
GFDERHAYI —————— ——GGMF:

SEQ ID NO
SEQ ID NO

46
47

vault PARP

APPGYDSVHGVSQTASVTTDF:

SEQ ID NO

48

The ?nding of the PXXP motif prompted an immediate
search for regions of the PARP-1 sequence With no knoWn

function, but With a high probability of beta sheet prediction
using the algorithm of StultZ C M, White J V, & Smith T F,
Protein Sci. 2(3): 305e14 (1993). Since the structure of

(1997). The name SH3 stands for the conserved Src-homol

ogy domain 3 found in Src-family tyrosine kinases. Along
With the SH2 domain, SH3 domains regulate the activation

SEQ ID NO

25

CF-PARP-l is knoWn, the search focused on the N-terminal
fragment, Which contains an assigned domain of no clear

function (C domain).

and the localiZation targeting of Src-kinases. Williams J C et

We performed a secondary structure prediction of PARP-1

al., Trends Biochem. Sci. 23(5): 179*84 (1998). The SH3

N-terminal domain, including predictions for beta sheet,

domain is a small (~60 residues) domain With over 250
representative sequences in the SWISSPROT database
(SEQ ID NO: 1). All SH3 domains fold into a compact
structure made up of tWo anti-parallel beta sheets of four

alpha helix and turns and solvent accessibility. The results
30

mapped, the secondary structure prediction focused on the
region betWeen the N-terminal Zinc ?ngers and the BRCT
domain. This region betWeen residues 240 and 400 (human

stands connected by loops of varying siZes (RT-loop and
n-src loop, see, FIG. 4). The general peptide-binding surface
of the SH3 module is made up of a cluster of aromatic

35

residues, forming three pockets. The tWo prolines of the core
motif PXXP (the SH3-ligand; SEQ ID NO: 2) bind to tWo

The sequence of PARP-1 betWeen residues 280e350 Was
40

compared With sequences of other SH3 domains of knoWn
structure obtained from the Protein Data Bank (PDB) data

45

base. The Protein Data Bank is operated by Rutgers, The
State University of NeW Jersey; the San Diego Supercom
puter Center at the University of California, San Diego; and
the National Institute of Standards and Technologyithree
members of the Research Collaboratory for Structural Bio

PARP-1 contains an SH3 domain and an SH3-ligand

domain. During an analysis of an alignment of several PARP
sequences, We found that PARP-1 contains a previously

unknown SH3 domain (SEQ ID NO: 30) and a previously
unknown SH3-ligand domain (SEQ ID NO: 34). FIG. 1A
shoWs the location of the predicted SH3 and SH3-ligand

informatics (RCSB). FIG. 6 is a sequence alignment of a

select group of SH3 domains (top 7 sequences) Whose
structures have been determined and deposited in the PDB
database. The ?rst three letters of the sequence identi?cation

domains in PARP-1 and shoWs that these domains are not

present in the other members of the PARP family of proteins.
From this analysis, the CF-fragment of PARP-1, Whose

50

indicates the PDB code: 1AEY (SEQ ID NO: 21); 1AOJ_A

(SEQ ID NO: 22); 1AZE_A (SEQ ID NO: 23); 1AON_B
(SEQ ID NO: 24); 1ABO_A (SEQ ID NO: 25); 1ARK (SEQ

structure had been determined, Was found to contain a PXXP

sequence localiZed Within a surface accessible loop, Which
leads to the active site of PARP-1 (FIG. 3 and FIG. 5). The
sequence contained a conserved arginine residue (R778,
human sequence; SEQ ID NO: 4) found at the N-terminal
end of the PXXP, With a three-residue spacing betWeen R778
and the ?rst proline P881 of the PXXP motif (see, TABLE
I, beloW). This is one residue longer than that expected for
a standard class I SH3 ligand. The proline-rich binding
domain Within the human PARP-1 sequence contains the
sequence: RIAPPEAPNT (SEQ ID. NO: 35), conforming to
the classic PXXP motif.
TABLE I shoWs a selected portion of the sequence
alignment of PARP family betWeen residues 656e1014
found Within a loop connecting beta strand 1 and 2 of the
core ADPRT fold (FIG. 2). Only PARP-1 and PARP-2

sequence) shoWed a 60 reside region With a mostly beta
sheet prediction Within the PARP-1 C domain (see, FIG.

1A).

hydrophobic pockets containing conserved aromatic resi
dues, While a third pocket is usually lined up With negative
charges and usually interacts With a positively charged
residue of the ligand. Kardinal C et al., Ann. NY Acad. Sci.
886: 289e92 (1999).

support the existence of a SH3 domain Within the PARP-1
C domain. Since most of the PARP-1 domains have been

ID NO: 26); P53BP (SEQ ID NO: 29). The bottom 6
sequences are those from the C domain of PARP-1 from
55

mouse (P_mussh3; SEQ ID NO: 28), rat (P_ratsh3; SEQ ID
NO: 29), human (P_humsh3; SEQ ID NO: 30), bovine

(P_bovsh3; SEQ ID NO: 31), chicken (P_chksh3; SEQ ID
NO: 32) and Xenopus (P_xensh3; SEQ ID NO: 33).
FIG. 6 shoWs the conserved sequences among the SH3
60

domains. The determination of Which sequences are con

served, as Well as guidance for the possible substitution of
an equivalent amino acid for any amino acid in a peptide

65

sequence, thereby maintaining the structure and function of
the polypeptide, is Well-knoWn to those of skill in the
molecular biological arts (see, Alberts B et al., Molecular

Biology of the Cell. 3rd ed. (NeW York: Garland Publishing,
1994); LeWin B, Genes VI. (New York, Oxford University

US 7,072,771 B2
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Press, 1997); Lodish H et al., Molecular Cell Biology. 4th
ed. (New York, W. H. Freeman and Company, 1999);

Since PARP-l activity is known to require dimer formation,
dimeriZation

Strachan T & ReadA P, Human Molecular Genetics, 2nd ed.

involves

the

inter-molecular interaction

between the SH3 domain of one monomer and the SH3
ligand of a second PARP-l monomer. Since activation

(New York: John Wiley & Sons, 1999)). These determina
tions can be performed using commercially available com

Based on the conserved sequences of the conserved
sequences of the six PARP-l SH3 domains in FIG. 6, a

depends on DNA binding, this may trigger dimeriZation, as
shown in FIG. 1B. According to FIG. 1B, dimeriZation
through PARP-1-SH3 puts the automodi?cation/BRCT
domain in close proximity to the catalytic domain. FIG. 7
shows two structural possibilities.
This approach to understanding the PARP-l mechanism

consensus

of action is a classic one, where the PARP-l domains are

puter programs, such as DNA Strider and Wisconsin GCG.
These determinations can also be performed using more

sophisticated molecular modeling software, such as Insight
II, described in EXAMPLE 3.

PARP-l

SH3

domain

can be

written

as

separated from the full-length protein and the behavior of
the separate units identi?ed. Understanding how these

DRVXDGMXFGALLPCXECSGQXVFKX
DAYYCXGDXXAWTKCXXKTQXPXRKXWVX

domains function individually enables us to address their
function in the context of the full length PARP-l and

PKEFXEIXYL (SEQ ID NO: 1))
The sequence comparison of PARP-l C domain with that

determine potential cooperativity between domains during

of a select group of SH3 domains with known 3D-structure
revealed a set of conserved aromatic residues that map to the

peptide-binding surface of SH3 domains. The sequence
variability is restricted to three loop regions of the SH3; two

PARP-l activation.

The discovery of the proline-rich sequence in PARP-l
20

of them are the RT and n-src loop, which surround the

peptide-binding surface. The sequence comparison below

tion and not its catalytic activity. This approach includes the

also reveals that PARP-1-SH3 likely belongs to a separate

generation and use of peptide inhibitors or peptide mimics of

subgroup. The ?rst subgroup represented by the top six
sequences represents the classic SH3 domain with recogni
tion favoring class I peptides with an arginine residue at the
N-terminal end of the PXXP motif. The second subgroup is

25

represented by P53 binding protein (P53BP), which by far
has the largest insertions in the n-src loop and the loop
connecting S3 to S4. The PARP-l vertebrate sequences form
the third subgroup, which in terms of siZe of its loop is closer
to subgroup I.
As shown in FIG. 6, the hydrophobic residues that make

40

(SEQ ID NO: 36). This suggests that at least one set of
aromatic motifs must be conserved in the SH3 module.

tive effects in vitro and signi?cant protective effects in shock
and reperfusion in vivo. Ha et al., Neurobiol. 7(4):225*39
(2000), showed that PARP-l over-activation caused by
cellular insults appears to play a prominent role in stroke and
other neurodegenerative processes in which PARP-l gene

Moreover, a published random mutagenesis experiment
45

deletion and PARP-l inhibiting drugs provide protection.
Mabley, et al., Br. J. Pharmacol. 133(6):909*19 (2001),
investigated the role of PARP in mediating the induction of
diabetes and [3-cell death in the multiple-low-dose-strepto
Zotocin (MLDS) model of type 1 diabetes. An inhibitor of

activation de?cient mutants of PARP-l that were still

capable of binding to DNA and retaining basal level of
activity. The Trucco experiments of revealed a point muta
tion within domain C, G313E mutation (SEQ ID NO: 37),

Jagtap et al., Criz. Care Med. 30(5):1071*82 (2002)
developed phenanthridinone PARP-l inhibitors and tested
them in vivo and in vivo for the ability to reduce PARP
activation and to protect against various cytotoxic events.
The compounds were shown to have signi?cant cryoprotec

does not conserve the C-terminal aromatic motif FXXPXXY

had been performed in PARP-l, where Trucco et al., Mol.
Cell Biochem. 193(1*2): 53*60 (1999) were looking for

all PARP-l inhibitors lack selectivity. By contrast, the
invention provides methods of selectively targeting PARP-l
for designing therapeutic compounds that are radio- and/or
chemosensitiZing, for example, or for developing therapeu
tic agents for stroke or diabetes type 1.

35

region contains a conserved proline at the beginning.
PARP-l -SH3 differs from other SH3 domain in the lack of
conservation of the YDF motif (SEQ ID NO: 19) at the
N-terminal end (see FIG. 5). A break in aromatic conserva
tion is also found in P53-binding protein SH3 domain, which

proline-rich sequence.
The importance of this ?nding is strengthened by the
discovery of several PARP-l-like proteins containing a
highly conserved catalytic domain. However, these PARP-l
inhibitors have targeted the catalytic domain and as a result,

30

up the SH3 core are conserved in PARP-l SH3. Five strands

(S1, S2, S3, S4, S5) form the SH3 domain. A single helical

opens a new area for the design of selective inhibitors of
PARP-l that focuses on the mechanism of PARP-l activa

50

PARP was found to protect mice from MLDS and prevent

[3-cell loss, in a dose dependent manner. These publications
provide evidence that the activation of PARP contributes to

which generated an “activation de?cient mutant”. Trucco
suggested that the de?ciency of the G313E mutant was a

result of either an “induced strong change in the tertiary

[3-cell damage and death in the MLDS model of diabetes,

structure of the enZyme or plays an important role in
self-association and/or in heterodimeriZation with other pro

and indicate a use for PARP activation in cytokine-mediated
55

teins.” Viewing the Trucco interpretation in light of our SH3
and SH3-ligand domain assignments, domain C may be
involved in protein interactions, which is herein proposed to
be a novel SH3, SH3-ligand interaction.
Thus, the existence of a PARP-l SH3 domain shows that

The details of one or more embodiments of the invention

are set forth in the accompanying description above.
Although any methods and materials similar or equivalent to
those described herein can be used in the practice or testing
60

of the present invention, the preferred methods and materials

65

are now described. Other features, objects, and advantages
of the invention will be apparent from the description and
from the claims. In the speci?cation and the appended
claims, the singular forms include plural referents unless the
context clearly dictates otherwise. Unless de?ned otherwise,

PARP-l can be activated by cytoplasmic proteins, indepen
dent of DNA damage. Based upon the deduced existence of
a PARP-1-SH3 and SH3 ligand domains, a model for
PARP-l activation upon DNA recognition has been formed.
The model is summariZed in FIG. 1C, which shows that

DNA recognition by the Zinc ?ngers, Z1 and ZII, triggers
PARP-l activation, through SH3 and SH3-ligand domains.

depression of insulin secretion and cell viability in vitro.

all technical and scienti?c terms used herein have the same

meaning as commonly understood by one of ordinary skill
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in the art to Which this invention belongs. All patents and

In particular, the full length PARP-l and its mutants are

publications cited in this speci?cation are incorporated by

expressed in Sf9 insect cell/baculovirus system and puri?ed

reference.
The following EXAMPLES are presented in order to
more fully illustrate the preferred embodiments of the inven

using an af?nity chromatography on 3-aminobenzamide
A?-Gel 10, Which Was also used in the crystallization of the

tion. These EXAMPLES should in no Way be construed as

(1999).

CF-PARP-l. Decker P et al., Clin. Cancer Res. 5: 1169*72

Site directed mutagenesis is performed using Quick

limiting the scope of the invention, as de?ned by the

appended claims.

Change® method (Stratagene). All mutations are performed
on a subclone of PARP-l containing either the catalytic
fragment of PARP-l or the domain C of PARP-l (see, FIG.

EXAMPLE 1

1A). Each subclone is engineered With unique restriction
PARP-l Bacterial Expression Vectors

sites at both ends alloWing us to piece together a point
mutated full length PARP-l.

A fragment containing PARP-1-SH3, residues 28(k340

The PARP-l activation assay is as described by Rolli V et

Was PCR cloned using primers with BamHI and Xhol
restriction sites. The fragment Was cloned into tWo expres

al., Biochemistry 36: 1214754 (1997). The DNA binding
assay is performed as described by GradWohl G et al, Proc.
Natl. Acad. Sci. USA 87: 299(L4 (1990).

sion vectors, Pet28a (Novagen) and PEGX (Stratagene).
The tWo vectors contain a histidine tag and a GST fusion

protein respectively. These tWo tags serve tWo purposes: (1)
for use in a single step puri?cation of PARP-1-SH3 folloWed
by removal of the tag using a thrombin cleavage site (The
thrombin used in the cleavage reaction can be removed by

20

Also, the PXXP motif is disrupted With the mutations,
P881A (SEQ ID NO: 38), P882A (SEQ ID NO: 39) and
P885A (SEQ ID NO: 40), all of Which disable the PPll
structure and consequently disable PARP-l activation. The
ability of PARP-l mutants to bind to DNA and its basal level

using biotinylated thrombin); and (2) the PGEX vector

of activity serves as a control that the mutations are not

containing the GST fusion protein also serves the purpose of

disabling as to catalytic activity or DNA binding.
The mutations in PARP-l SH3 could conceptually gen
erate three potential phenotypes: (1) a constitutively active
PARP-l, (2) an activation knockout of PARP-l; or (3) Wild
type PARP-l (unlikely). Constitutive active mutants Would
suggest that the C domain keeps PARP-l in the OFF state.
An activation knockout e?fect suggests either: (a) that
domain C is vital for turning catalytic activity ON, or (b) that
the mutation has disrupted PARP-l structure. The latter
possibility is investigated as shoWn beloW. The observation

enhancing the solubility of the recombinant protein.

25

The fragment can be subcloned into a pTYB(NEB) vec

tor, Which attaches a chitin binding/intein self-cleaving
domain. Chong S et al., Gene 192(2): 271*81 (1997). After
induction With IPTG, the fusion protein is puri?ed using a
chitin-binding column. Once the fusion protein is attached to
the column, DTT is added to induce the self-cleaving

30

activity of intein. The puri?ed native protein is eluted While
the intein domain remains attached to the column.
An SDS PAGE gel has been used to separate the GST

puri?ed fusion protein and the thrombin cleaved fragment,
releasing the 6 kDa SH3 fragment.

35

of a Wild type phenotype for all the seven mutations is
unlikely, since there is experimental data maps an activation
de?cient mutant of PARP-l to the SH3 domain.

Both of these constructs can noW be used to investigate

Structural Analysis by Characterization of the Solution

their ability to bind to full-length PARP-l using (1) a GST
pulldoWn assay and (2) a surface plasmon resonance assay

Structure of the Wild Type and Site-Directed Mutants of the

employing a BIACORE instrument. A PARP-l activation
assay in the presence of different domains can be used to

40

identify interactions necessary for activation.
EXAMPLE 2

SH3 Domain by Circular Dichroism and Screening for
Crystallization Conditions. Circular Dichroism (CD) mea
surements provide a fast, relatively simple and established
method for estimating the relative content of protein sec
ondary structure. CD measurements With the puri?ed frag
ment of PARP-l SH3 support the deduced beta sheet struc

45

Structure/ Function Testing

ture, supporting the fold model and enabling more elaborate
methods such as X-ray crystallography and/or NMR. The
CD experiments are also performed on site-directed mutants

The binding of PARP-l to DNA strand breaks results in

its activation by the interaction of SH3 and SH3-ligand
domains. This model provides the rationale for the devel
opment of a neW drug discovery paradigm for generation of

50

not affected the molecular structure of PARP-l SH3.

PARP-l inhibitors for cancer therapy.
Functional Test of the Model Regarding the SH3 and

SH3-ligand Domains of PARP-l. Directed mutagenesis is
used to generate single amino acid changes to disrupt the
peptide recognition surface of the PARP-l SH3 domain and
the SH3-ligand domain. Disruption of either domain results

The structure determination of PARP-l SH3 using X-ray

crystallographic techniques provides the ultimate evidence
of an SH3 fold.
55

The predicted SH3 domain of PARP-l and the site
directed mutants of PARP-l SH3 domain are expressed as a

GST-fusion protein (PGEX vector, Pharmacia/LKB Tech
nology) and a polyhistidine-tag (HIS-tag) vector (Pet28c,

in a PARP-l that is unable to be activated by DNA strand
breaks.
Human PARP-l SH3 is mutated at residues that map to a

of PARP-l SH3 (see, above). Since these mutations are
designed to alter surface properties and not the predicted
SH3, the results provide a control that the mutations have

Novagen). The tags are useful for the puri?cation of the
60

predicted SH3 domain and can be cleaved off using a

conserved, and predominately aromatic surface (L293A,
P294A, C295A, W318A, W333A, P336A and F339A)

biotinylated thrombin, enabling the capture of the thrombin

involved in the recognition of the proline-rich PXXP SH3
ligand (PPH). The site-directed mutants are designed to
maintain structural integrity of the SH3 domain, While
disrupting its ability to interact With the SH3 -ligand found in

CONTIN (Bousquet J A et al., Biochemistry 39, 7722*35

CF-PARP-l (TABLE 1).

(Novagen). The CD spectra are measured and program

65

(2000)) used to extract secondary structure content.
The expressed PARP-l SH3 peptides are also screened for

crystallization, to determine the structure using crystallo
graphic techniques. 3D-structures of the SH3 domains of

US 7,072,771 B2
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other proteins are known, thus providing guidance for the

Guidance for a comparison of structural and dynamic
properties of di?cerent simulation methods applied to SH3
can be found in scienti?c publications, including van Aalten
V M F et al., Biophys. J. 70: 6844692 (1996), Hansson H et

analysis of PARP-l SH3 structure.
Structure/Function Test of the Physical Interaction of

PARP-l SH3 and SH3-ligand Domains By Direct Binding
Experiments. To shoW that PARP-l contains a functional
SH3 domain involved in its activation, the SH3 domain
should be shoWn to bind directly to the SH3 -ligand found in
CF-PARP-l.
Binding of the GST-SH3 fusion construct With the cata

al., Biochemistry (2001), and Garbay C et al., Biochem.
Pharmacol. 60(8): 116549 (2000), among others.

lytic fragment of PARP-l (CF-PARP-l) is assayed using

Structural/Functional Model of the L613F PARP-l
Mutant

EXAMPLE 4

glutathione beads to immobilize GST-SH3. Complex detec
tion are done using Western blots With anti-GST and com
mercial PARP-l antibodies. CF-PARP-l mutants that dis

To achieve selective targeting of the PARP-l enZyme, We

rupt the putative polyproline helix II (PPH) (SH3-ligand

investigated the structure of the PARP-l protein and the

domain) are used as a negative control.

mechanism of PARP-l activation upon DNA damage rec

ognition.

Binding assays folloW procedures used for characteriza

The sequence of PARP-l has a unique set of domains,
including tWo Zinc ?nger DNA binding domain and a

tion of SH3 domains. Mosser EA et al., Biochemistry 37:
13686495 (1998). The GST and HIS-tags are used to immo
biliZe the SH3 domain. Then, binding of PARP-l SH3 to
CF-PARP-l and mutants of CF-PARP-l With alterations in

the SH3-ligand domain (PXXP motif, FIG. 3) is tested as
follows: RIAAAEAP (SEQ ID NO:41), RIAPAEAA (SEQ
ID NO: 42) and RIAAPEAA (SEQ ID NO: 43). Commercial
antibodies against GST, HIS-tag and CF-PARP-l are used in
Western blots to identify protein complexes. The ability of

conserved C-terminal domain similar to the breast cancer 1
20

25

PARP-l SH3 to interfere or compete With the natural SH3

68476 (1997). Also, PARP-l contains a src homology 3 like
domain (SH3) and SH3 ligand domains. Macias M. J et al.,
FEBS Len. 513(1): 3047 (2002). Furthermore, the G313E
mutation (SEQ ID NO: 37) interferes selectively With the
mechanism of activation of PARP-l and maps to the PARP
1-SH3.
Based on these lines of evidence We developed a model

ligand is tested by adding increasing amounts of PARP-l
SH3 to the activation assay of Wild type PARP-l.
EXAMPLE 3

gene (BRCAl), Which is involved in protein-protein inter
action also called BRCT. Deng C X & Brodie S G, BioEs
says 22(8): p. 728437 (2000); Bork P et al., Faseb J. 11(1):

30

for PARP-l activation upon DNA recognition. Since

PARP-l activity requires dimer formation, dimeriZation

Molecular Modeling in Designing PARP-l

should involve the inter-molecular interaction betWeen the

Inhibitors

SH3 domain of one monomer and the SH3-ligand of a
second PARP-l monomer. This model is a classical

Based upon the noW determined structure of the SH3

35

domain and SH3-ligand domain of PARP-l, knoWn and
predicted compounds can be tested by molecular simulations

action, since We are ?rst separating the domains from the full
length PARP-l and then identifying their behavior as sepa
rate units. By ?rst understanding hoW these domains func

for interaction With PARP-l, using InsightII (Molecular
Visualization (MolViZ) Facility Department of Chemistry
Indiana University, Bloomington, Ind. USA) and other mod
eling softWare.

tion individually, We can then address their function in the
40

used by a molecular modeling computer program. The
45

program. Next, the structure of a compound suspected of
molecularly interacting With the PARP-l SH-3domain or the

PARP-l SH3-ligand domain is obtained. The “molecularly
interacting” can be covalent, ionic or other noncovalent

50

binding. Guidance for hoW the compound may molecularly
interact With these domains is provided above. Then, the
structure of the compound suspected of molecularly inter
acting With the PARP-l SH-3domain or the PARP-l SH3
ligand domain in a digital format that can be used by the

55

3). The tWo domains interact With each other through a loop
that contains a PXXP motif (SEQ ID NO: 2), Which should

be the ligand for the PARP-1-SH3 domain (see, FIG. 1B).
The mutation L613F maps the all alpha domain of CF
PARP-l right next to the PXXP loop. We produced the
60

ligand domain molecularly interacts With the compound
suspected of molecularly interacting With the PARP-l SH3
ligand domain, using the instructions provided by the

larly as being a potential therapeutic agent.

higher than Wild type PARP-l, in the absence of DNA.
Miranda EA et al., Biochem. Biophys. Res. Commun. 212(2):
317425 (1995). The mutation maps to the catalytic fragment
of PARP-l. The structure of the catalytic fragment of
PARP-l contains tWo domains, an all alpha domain and a

the compound suspected of molecularly interacting With the

molecular modeling softWare and methods knoWn to those
of skill in the bioinformatics art. Based upon this operation,
it is possible to identify a compound that interacts molecu

activation.
Accordingly, We have noW modeled a gain of function
mutation L613F that maps to the catalytic fragment of
PARP-l, Whose structure has been determined. (SEQ ID
NO: 18); RufA et al., Proc. Natl. Acad. Sci. USA. 93(15):
74815 (1996). This mutation generates a PARP-l protein
that has a catalytic poWer (km/KM) one order of magnitude

conserved ADP-ribosyltransferase domain (ADPRT) (FIG.

molecular modeling computer program. The molecular
modeling computer program is operated to determine (1)
Whether the PARP-l SH-3domain molecularly interacts With
PARP-l SH-3domain, or (2) Whether the PARP-l SH3

context of the full length PARP-l protein and determine

potential cooperativity betWeen domains during PARP-l

First, the structure of the PARP-l SH-3domain or the
PARP-l SH3-ligand domain in a digital format that can be

molecular modeling softWare generally provides informa
tion regarding Which digital format is acceptable for that

approach toWards understanding PARP-l mechanism of

structural L613F mutant model utiliZing the knoWn structure

of the catalytic fragment of PARP-l. The L613F mutation
involves an amino acid change to a bulkier hydrophobic
residue. This added bulkiness at position 613 a?cects the
structure of the neighboring loop that contains our PXXP
65

proline rich loop. This structural model is consistent With
our functional model that suggests that the binding of
PARP-1-SH3 to the PXXP loop found in the catalytic

US 7,072,771 B2
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fragment of PARP-l Which separate the tWo domains (all
alpha and ADPRT) operates in much the same Way that the
L613F alteration, Which provides a bulkier side chain,
affects the activity of CF-PARP-l.

Guidance as to the amount of peptide With sequence

RIAPPEAPV (SEQ ID NO: 7) that is suf?cient to bind to the
PARP-l SH3 domain and inactivate the PARP-l or func

tional fragment thereof is provided by comparison With the
amount of inhibitors (derivatives of benZamides and fused

ring heterocycles) used to target the conserved NAD binding
site (pADPRT domain) of PARP-l, Which present in all of
the PARP family members. Ruf A. et al., Biochemistry
37(11): 3893e900 (1998); Tentori L et al., Pharmacol Res.
45(2): 73e85 (2002); Jacobson M K & Jacobson E L, Trends
Biochem Sci. 24(11): 415e7 (1999). See also, US. Pat. Nos.

EXAMPLE 5

Drugs That are Selectively Designed For PARP-l
In one embodiment, small peptides With the sequence

RIAPPEAPV (SEQ ID NO: 7) compete With the natural
ligand of PARP-l. This sequence is unique to PARP-l and
should bind poorly to other SH3 domains, such as those that
are found in cell signaling molecules such as src-kinases. We
.

.

.

. .

.

6,201,020, 6,121,278, 5,587,384, 5,215,738; 5,041,653 and
5,032,617, each incorporated herein by reference. Assays to
measure an amount of a compound suf?cient to affect
15

PARP-l activity or inhibition are commercially available

generated bmdmg evldence unhmg the sq?ware SPOT-

(Trevigen® PARP Activity Assay Kit and Trevigen® PARP

SH3’ Whlch has been Shown to predlct the ablhty of pepnde

Inhibition Assay Kit‘ Trevigen Inc. 8405 Helgerman Court

sequences to bind to SH3 domains. Brannetti B et al., J. Mol.

Gaithersburg M d {ISA 2087’7)
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305415 (2002).
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PXXP sequence With a predicted score in the range 0.7 to

0.9. By contrast, by utiliZing the PARP-l SH3 ligand
sequence, We obtain only a score of 0.6. This result shoWs

that the PARP-l proline-rich sequence RIAPPEAPV should
bind poorly to other SH3 sequences, so that peptides With
sequence RIAPPEAPV (SEQ ID NO: 7) selectively bind to
PARP-l and inhibit its activity.

25

for other SH3 domain proteins. Nguyen J T et al., Chem.
Biol. 7(7): 463e73 (2000). NoW, the use of peptide mimics
is a useful strategy for increasing the binding potency of
peptide ligands to PARP-1-SH3.

The foregoing description has been presented only for the
purposes of illustration and is not intended to limit the

invention to the precise form disclosed, but by the claims

appended hereto.

SEQUENCE LISTING

<l60> NUMBER OF SEQ ID NOS: 48

<2 10> SEQ ID NO 1
<2ll> LENGTH: 65
<2 12> TYPE: PRT

ORGANISM: Homo sapiens
<400> SEQUENCE: l

Asp Arg Val Ala Asp Gly Met Val Phe Gly Ala Leu Leu Pro Cys Glu
5

10

15

Glu Cys Ser Gly Gln Leu Val Phe Lys Ser Asp Ala Tyr Tyr Cys Thr
20

25

30

Gly Asp Val Thr Ala Trp Thr Lys Cys Met Val Lys Thr Gln Thr Pro
35

40

Arg Lys Glu Trp Val Thr Pro Lys Glu Phe Arg Glu Ile Ser Tyr
50

55

60

Leu

65

SEQ ID NO 2
LENGTH: 4
TYPE: PRT
ORGANISM: Homo
FEATURE:

sapiens

NAME/KEY: MODLRES
LOCATION: (2)..(3)
OTHER INFORMATION: Any amino acid except Pro
<400> SEQUENCE: 2
Pro Xaa Xaa Pro

1

’

20 been successfully used in the design of selective inhibitors

Natural ligands of other SH3 domain bind their ligand

l

’

The use of peptide mimics is a strategy that has already

